XML 65 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
Business Combination - Total Purchase Consideration (Details) - Antares Pharma, Inc - USD ($)
$ in Thousands
12 Months Ended
May 24, 2022
Dec. 31, 2022
Business Acquisition [Line Items]    
Cash consideration for Antares shares outstanding as of May 24, 2022 $ 956,886  
Consideration for Antares equity compensation awards 45,828  
Consideration for seller transaction costs paid by Halozyme 22,906  
Consideration related to Antares closing indebtedness settled by Halozyme 19,683  
Cash consideration related to cash bonus awards paid by Halozyme 365  
Total purchase consideration 1,045,668  
Unvested equity awards attributable to the post-combination period   $ 8,700
Equity Compensation Awards, Vested    
Business Acquisition [Line Items]    
Consideration for Antares equity compensation awards 32,200  
Equity Compensation Awards, Unvested    
Business Acquisition [Line Items]    
Consideration for Antares equity compensation awards $ 13,600